These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20456395)

  • 1. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.
    Hirahara K; Kano Y; Mitsuyama Y; Takahashi R; Kimishima M; Shiohara T
    Clin Exp Dermatol; 2010 Dec; 35(8):863-8. PubMed ID: 20456395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
    Teraki Y; Shibuya M; Izaki S
    Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
    Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
    J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
    Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
    Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
    Wolf R; Matz H; Marcos B; Orion E
    Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype standardization for immune-mediated drug-induced skin injury.
    Pirmohamed M; Friedmann PS; Molokhia M; Loke YK; Smith C; Phillips E; La Grenade L; Carleton B; Papaluca-Amati M; Demoly P; Shear NH
    Clin Pharmacol Ther; 2011 Jun; 89(6):896-901. PubMed ID: 21562486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Choon SE; Lai NM
    Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China.
    Li LF; Ma C
    Clin Exp Dermatol; 2006 Sep; 31(5):642-7. PubMed ID: 16901302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
    Viera MH; Perez OA; Patel JK; Jones I; Berman B
    Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
    Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
    Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
    Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
    Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential gene expression in drug hypersensitivity reactions: induction of alarmins in severe bullous diseases.
    Bellón T; Alvarez L; Mayorga C; Morel E; Torres MJ; Martín-Díaz MA; Díaz R; Radial A; Carballo M; Blanca M
    Br J Dermatol; 2010 May; 162(5):1014-22. PubMed ID: 20030638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Teraki Y; Kawabe M; Izaki S
    J Allergy Clin Immunol; 2013 Mar; 131(3):907-9. PubMed ID: 23083672
    [No Abstract]   [Full Text] [Related]  

  • 15. Expression of α-defensin 1-3 in T cells from severe cutaneous drug-induced hypersensitivity reactions.
    Morel E; Alvarez L; Cabañas R; Fiandor A; Díaz R; Escamochero S; Prior N; Blanca M; Bellón T
    Allergy; 2011 Mar; 66(3):360-7. PubMed ID: 20880148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment.
    Murata J; Abe R; Shimizu H
    J Allergy Clin Immunol; 2008 Nov; 122(5):992-1000. PubMed ID: 18692887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
    Ding WY; Lee CK; Choon SE
    Int J Dermatol; 2010 Jul; 49(7):834-41. PubMed ID: 20618508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions.
    Barbaud A; Collet E; Milpied B; Assier H; Staumont D; Avenel-Audran M; Grange A; Amarger S; Girardin P; Guinnepain MT; Truchetet F; Lasek A; Waton J;
    Br J Dermatol; 2013 Mar; 168(3):555-62. PubMed ID: 23136927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
    Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
    Br J Dermatol; 2006 Feb; 154(2):319-24. PubMed ID: 16433803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.